Pfizer raises 2026 revenue outlook after second-quarter earnings beat estimates

Earnings
โดย Proactive·Read original
Summary · why it matters

Pfizer raised the midpoint of its full-year 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion after second-quarter results topped Wall Street expectations. The company reported adjusted earnings of $0.77 per share, above the $0.68 consensus, on revenue of $15.03 billion versus the $14.40 billion estimate. Excluding COVID-19 products Comirnaty and Paxlovid, revenue rose 5% operationally, while launched and acquired products grew 18% operationally. Pfizer reaffirmed its adjusted diluted earnings guidance of $2.80 to $3.00 per share and announced an additional $2.5 billion in anticipated productivity savings to be realized from 2027 through 2029. CEO Albert Bourla cited strong performance from launched and acquired products, momentum in the obesity program, and strength in the oncology portfolio.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Pfizer Inc
PFE
▲ PositiveCapitalrelevance

Q2 earnings beat and raised 2026 revenue guidance

© 2026 MarketDXNews